114 related articles for article (PubMed ID: 19117962)
1. SASAT (South Asian Society on Atherosclerosis & Thrombosis) proposal for regulatory guidelines for generic low-molecular weight heparins (LMWHs).
Kalodiki E; Leong W;
Clin Appl Thromb Hemost; 2009 Feb; 15(1):8-11. PubMed ID: 19117962
[No Abstract] [Full Text] [Related]
2. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
3. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
4. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
5. Development of generic low molecular weight heparins: a perspective.
Fareed J; Leong W; Hoppensteadt DA; Jeske WP; Walenga J; Bick RL
Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
[TBL] [Abstract][Full Text] [Related]
6. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
7. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
[TBL] [Abstract][Full Text] [Related]
8. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
10. The United States Food and Drugs Administration approves a generic enoxaparin.
Ofosu FA
Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
[TBL] [Abstract][Full Text] [Related]
11. Generic and commercial low molecular weight heparins.
Messmore HL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):253. PubMed ID: 16959678
[No Abstract] [Full Text] [Related]
12. The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products.
Fareed J; Bick RL; Rao G; Goldhaber SZ; Sasahara A; Messmore HL; Happensteadt DA; Nicolaides A; ; ; ;
Clin Appl Thromb Hemost; 2008 Jan; 14(1):5-7. PubMed ID: 18182679
[No Abstract] [Full Text] [Related]
13. Generic forms of low-molecular-weight heparins: some practical considerations.
Leong W; Hoppensteadt DA
Clin Appl Thromb Hemost; 2003 Oct; 9(4):293-7. PubMed ID: 14653438
[TBL] [Abstract][Full Text] [Related]
14. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.
Cohen M; Jeske WP; Nicolau JC; Montalescot G; Fareed J
J Thromb Thrombolysis; 2012 Apr; 33(3):230-8. PubMed ID: 22234748
[TBL] [Abstract][Full Text] [Related]
15. Variability of heparins and heterogeneity of low molecular weight heparins.
Bianchini P; Liverani L; Spelta F; Mascellani G; Parma B
Semin Thromb Hemost; 2007 Jul; 33(5):496-502. PubMed ID: 17629846
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy.
Guerrini M; Guglieri S; Naggi A; Sasisekharan R; Torri G
Semin Thromb Hemost; 2007 Jul; 33(5):478-87. PubMed ID: 17629844
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
18. Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology.
Hoppensteadt DA; Fareed J; Bick RL
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():105-8. PubMed ID: 15085471
[No Abstract] [Full Text] [Related]
19. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
Nicolau JC; Cohen M; Montalescot G
J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
[TBL] [Abstract][Full Text] [Related]
20. Quantitative PCR and disaccharide profiling to characterize the animal origin of low-molecular-weight heparins.
Houiste C; Auguste C; Macrez C; Dereux S; Derouet A; Anger P
Clin Appl Thromb Hemost; 2009 Feb; 15(1):50-8. PubMed ID: 18805847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
